alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 520.1242b Levamisol boluses or oblets. ( a ) *Specifications.* Each bolus contains 2.19 grams levamisol hydrochloride. Each oblet contains 0.184 grams levamisol hydrochloride.
( b ) *Sponsors.* See Nos. 000061 and 054771 in § 510.600(c) of this chapter.
( c ) *Required labeling.* Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
( d ) *Related tolerances.* See § 556.350 of this chapter.
( e ) *Conditions of use* — ( 1 ) *Cattle* — ( i ) *Amount.* Administer orally 2.19-gram boluses as a single dose as follows: 250 to 450 pounds, 1 ⁄ 2 bolus; 450 to 750 pounds, 1 bolus; and 750 to 1,050 pounds, 11 ⁄ 2 boluses.
( ii ) *Indications for use.* Anthelmintic effective against the following nematode infections: Stomach worms (*Haemonchus, Trichostrongylus,* *Ostertagia*), intestinal worms (*Trichostrongylus, Cooperia,* *Nematodirus, Bunostomum,* *Oesophagostomum*), and lungworms (*Dictyocaulus*).
( iii ) *Limitations.* Conditions of constant helminth exposure may require re-treatment within 2 to 4 weeks after the first treatment. Do not slaughter for food within 48 hours of treatment. Not for use in dairy animals of breeding age. Consult veterinarian before using in severely debilitated animals.
( 2 ) *Sheep* — ( i ) *Amount.* Administer orally one 0.184-gram oblet for each 50 pounds of body weight.
( ii ) *Indications for use.* Anthelmintic effective against the following nematode infections: Stomach worms (*Haemonchus, Trichostrongylus,* *Ostertagia*), intestinal worms (*Trichostrongylus, Cooperia,* *Nematodirus, Bunostomum,* *Oesophagostomum, Chabertia*), and lungworms (*Dictyocaulus*).
( iii ) *Limitations.* Conditions of constant helminth exposure may require re-treatment within 2 to 4 weeks after the first treatment. Do not slaughter for food within 72 hours of treatment. Consult a veterinarian before using in severely debilitated animals.
[78 FR 28822, May 20, 2014]
§ 50.53 Clinical investigations involving greater than minimal risk and no prospect of direct benefit to individual subjects, but likely to yield generalizable knowledge about the subjects' disorder or condition. Any clinical investigation within the scope described in §§ 50.1 and 56.101 of this chapter in which more than minimal risk to children is presented by an intervention or procedure that does not hold out the prospect of direct benefit for the individual subject, or by a monitoring procedure that is not likely to contribute to the well-being of the subject, may involve children as subjects only if the IRB finds that: ( a ) The risk represents a minor increase over minimal risk;
( b ) The intervention or procedure presents experiences to subjects that are reasonably commensurate with those inherent in their actual or expected medical, dental, psychological, social, or educational situations;
( c ) The intervention or procedure is likely to yield generalizable knowledge about the subjects' disorder or condition that is of vital importance for the understanding or amelioration of the subjects' disorder or condition; and
( d ) Adequate provisions are made for soliciting the assent of the children and permission of their parents or guardians as set forth in § 50.55.
[66 FR 20598, Apr. 24, 2001, as amended at 78 FR 12951, Feb. 26, 2013]
#### § 514.201 Procedures for hearings.

Hearings relating to new animal drugs under section 512(d) and (e) of the act shall be governed by part 12 of this chapter.

[64 FR 63204, Nov. 19, 1999]
[Federal Register Volume 75, Number 37 (Thursday, February 25, 2010)]
[Notices]
[Page 8718]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3995]


=======================================================================
-----------------------------------------------------------------------

FEDERAL MINE SAFETY AND HEALTH REVIEW COMMISSION


Sunshine Act Notice

February 17, 2010.

TIME AND DATE:  10 a.m., Thursday, March 4, 2010.

PLACE:  The Richard V. Backley Hearing Room, 9th Floor, 601 New Jersey 
Avenue, NW., Washington, DC.

STATUS:  Open.

MATTERS TO BE CONSIDERED: The Commission will consider and act upon the 
following in open session: Secretary of Labor v. Wolf Run Mining 
Company, Docket No. WEVA 2008-804. (Issues include whether a violation 
of a safeguard notice issued by the Secretary may be designated as 
``significant and substantial.'')
    Any person attending this meeting who requires special 
accessibility features and/or auxiliary aids, such as sign language 
interpreters, must inform the Commission in advance of those needs. 
Subject to 29 CFR 2706.150(a)(3) and 2706.160(d).

CONTACT PERSON FOR MORE INFORMATION:  Jean Ellen (202) 434-9950/(202) 
708-9300 for TDD Relay/1-800-877-8339 for toll free.

Jean H. Ellen,
Chief Docket Clerk.
[FR Doc. 2010-3995 Filed 2-23-10; 4:15 pm]
BILLING CODE P
§ 522.2670 Yohimbine. ( a ) *Specifications.* Each milliliter (mL) of solution contains 2 or 5 milligrams (mg) of yohimbine (as hydrochloride).
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter for use as in paragraph (c) of this section. ( 1 ) No. 059399 for use of in 2 mg/mL solution as in paragraph (c)(1) of this section.
( 2 ) No. 053923 for use of in 5 mg/mL solution as in paragraph (c)(2) of this section.
( c ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* Administer 0.05 mg per pound (0.11 mg per kilogram) of body weight by intravenous injection.
( ii ) *Indications for use.* To reverse the effects of xylazine in dogs.
( iii ) *Limitations.* Not for use in food-producing animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Deer and elk* — ( i ) *Amount.* Administer 0.2 to 0.3 mg per kilogram of body weight by intravenous injection.
( ii ) *Indications for use.* A s an antagonist to xylazine sedation in free ranging or confined members of the family Cervidae (deer and elk).
( iii ) *Limitations.* Do not use in domestic food-producing animals. Do not use for 30 days before or during hunting season. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 74020, Dec. 15, 2014, as amended at 80 FR 13230, Mar. 13, 2015]
§ 522.1883 Prednisolone sodium phosphate. ( a ) *Specifications.* Each milliliter of solution contains 20 milligrams (mg) prednisolone sodium phosphate (equivalent to 14.88 mg of prednisolone).
( b ) *Sponsor.* See No. 061133 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer intravenously in a dosage of 21 ⁄ 2 to 5 mg per pound of body weight, initially for shock and shock-like states, followed by equal maintenance doses at 1-, 3-, 6-, or 10-hour intervals as determined by the condition of the animal.
( 2 ) *Indications for use.* Administer when a rapid adrenal glucocorticoid and/or anti-inflammatory effect is necessary.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[68 FR 59881, Oct. 20, 2003, as amended at 84 FR 8974, Mar. 13, 2019]
§ 556.426 Moxidectin. ( a ) *Acceptable daily intake (ADI).* The ADI for total residue of moxidectin is 4 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerances for moxidectin (marker residue) are: ( 1 ) *Cattle.* ( i ) Fat (target tissue): 900 ppb.
( ii ) Liver: 200 ppb.
( iii ) Muscle: 50 ppb.
( iv ) Milk: 40 ppb.
( 2 ) *Sheep.* ( i ) Fat (target tissue): 900 ppb.
( ii ) Liver: 200 ppb.
( iii ) Muscle: 50 ppb.
( c ) *Related conditions of use.* See §§ 520.1454, 522.1450, and 524.1450 of this chapter.
**EXHIBIT 23.1**
**CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS**
     We consent to the incorporation by reference in the RegistrationStatements (Form S-3 No. 333-59861 and Form S-8 Nos. 333-00436 and 333-50983) pertaining to certain shares of KeraVision, Inc. common stockissuable to the holders of Series B convertible preferred stock, the 1997Employee Stock Option Plan, the 1995 Director's Stock Option Plan, the1995 Employee Stock Purchase Plan, the 1995 Stock Option Plan and the1987 Stock Option Plan of KeraVision, Inc. of our report dated February4, 2000, with respect to the consolidated financial statements ofKeraVision, Inc. included in its Annual Report (Form 10-K) for the yearended December 31, 1999.
San Jose, California March 28, 2000
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.41 Comment and advice on an IND. ( a ) FDA may at any time during the course of the investigation communicate with the sponsor orally or in writing about deficiencies in the IND or about FDA's need for more data or information.
( b ) On the sponsor's request, FDA will provide advice on specific matters relating to an IND. Examples of such advice may include advice on the adequacy of technical data to support an investigational plan, on the design of a clinical trial, and on whether proposed investigations are likely to produce the data and information that is needed to meet requirements for a marketing application.
( c ) Unless the communication is accompanied by a clinical hold order under § 312.42, FDA communications with a sponsor under this section are solely advisory and do not require any modification in the planned or ongoing clinical investigations or response to the agency.
[52 FR 8831, Mar. 19, 1987, as amended at 52 FR 23031, June 17, 1987; 67 FR 9586, Mar. 4, 2002]
UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

OAKLAND DIVISION

 

WILDEARTH GUARDIANS, )

)

Plaintiff )

)

)

v. ) CASE NO. 4:09-CV-02453-CW 

)

)

LISA JACKSON, in her official capacity as )

Administrator of the Environmental Protection Agency )

)

Defendant )

 

ORDER GRANTING

JOINT MOTION TO MODIFY CONSENT DECREE

Upon consideration of the Joint Motion to Modify Consent Decree, the Motion is

GRANTED. 

The Consent Decree entered on February 23, 2010 (Docket Entry 26) is hereby modified

to:

(1) extend the deadline in paragraph 7(a) of the Consent Decree from May 10, 2011 to

June 21, 2011 for the Administrator to sign a notice or notices approving a State Implementation

Plan (“SIP”), promulgating a Federal Implementation Plan (“FIP”), or approving a SIP in part

with promulgation of a partial FIP for Idaho, New Mexico, North Dakota, Oklahoma, and

Oregon to meet the requirement of 42 U.S.C. § 7410(a)(2)(D)(i)(II) regarding interfering with

measures in other states related to protection of visibility; and

(2) require the Administrator to sign by March 15, 2011 a notice proposing either

approval of a SIP, promulgation of a FIP or approval of a SIP in part with promulgation of a

Case4:09-cv-02453-CW Document31 Filed01/14/11 Page1 of 2
2

partial FIP for North Dakota to meet the requirement of 42 U.S.C. § 7410(a)(2)(D)(i)(II)

regarding interfering with measures in other states related to protection of visibility.

IT IS SO ORDERED.

Date: 1/14/2011 ___________________

Claudia Wilken

United States District Judge

Case4:09-cv-02453-CW Document31 Filed01/14/11 Page2 of 2
# C_2014253EN.01001701.xml

| 4.8.2014 | EN | Official Journal of the European Union | C 253/17 |
| --- | --- | --- | --- |

4.8.2014

EN

Official Journal of the European Union

C 253/17

---

Request for a preliminary ruling from the Amtsgericht Laufen (Germany) lodged on 30 April 2014 — Criminal proceedings against Gavril Covaci

(Case C-216/14)

2014/C 253/22

Language of the case: German

Referring court

Referring court

Amtsgericht Laufen

Parties to the main proceedings

Parties to the main proceedings

Gavril Covaci

Other party: Staatsanwaltschaft Traunstein

Other party

Questions referred

Questions referred

| 1. | Are Articles 1(2), 2(1) and 8 of Directive 2010/64/EU (1) to be interpreted as precluding a court order that requires, under Paragraph 184 of the German Law on the Judicial System, accused persons to bring an appeal only in the language of the court, here in German, in order for it to be effective? |
| --- | --- |

1.

Are Articles 1(2), 2(1) and 8 of Directive 2010/64/EU (1) to be interpreted as precluding a court order that requires, under Paragraph 184 of the German Law on the Judicial System, accused persons to bring an appeal only in the language of the court, here in German, in order for it to be effective?

1

| 2. | Are Articles 2, 3(1)(c), 6(1) and 6(3) of Directive 2012/13/EU (2) to be interpreted as precluding the accused from being required to appoint a person authorised to accept service, where the period for bringing an appeal begins to run upon service on the person authorised and ultimately it is irrelevant whether the accused is at all aware of the offence of which he is accused? |
| --- | --- |

2.

Are Articles 2, 3(1)(c), 6(1) and 6(3) of Directive 2012/13/EU (2) to be interpreted as precluding the accused from being required to appoint a person authorised to accept service, where the period for bringing an appeal begins to run upon service on the person authorised and ultimately it is irrelevant whether the accused is at all aware of the offence of which he is accused?

2

---

(1)  Directive 2010/64/EU of the European Parliament and of the Council of 20 October 2010 on the right to interpretation and translation in criminal proceedings, OJ 2010 L 280, p. 1.

1

(2)  Directive 2012/13/EU of the European Parliament and of the Council of 22 May 2012 on the right to information in criminal proceedings, OJ 2012 L 142, p. 1.

2

---
<PAGE>   1

                                                                    EXHIBIT 10.2

                              DIRECTOR'S AGREEMENT

        This Agreement, dated as of November 10, 1998, is between UNITED
SECURITY BANCORPORATION, a Washington corporation ("USBN") and _____________
("Director"), a director of Bancwest Financial Corporation ("Bancwest") and/or
its wholly owned subsidiary, Bank of the West.

                                    RECITALS

        1. Pursuant to the terms of the Agreement and Plan of Merger, dated as
of November 10, 1998 ("Plan") between USBN, Bancwest, and Bank of the West,
Bancwest will merger into USBN and Bank of the West will become the wholly owned
subsidiary of USBN.

        2. USBN's obligation to consummate the transactions contemplated by the
Plan is conditioned upon their receipt of non-competition agreements from all
directors of the Bancwest and Bank of the West.

        3. Director is a director of Bancwest and/or Bank of the West and a
shareholder of Bancwest.

                                    AGREEMENT

        In consideration of USBN's performance under the Plan, Director agrees
that for a period of two years after the Effective Date, as defined in the Plan,
he or she will not, directly or indirectly, become involved in, as a principal
shareholder, director or officer, "founder," employee, or other agent of, any
financial institution or trust company that competes or will compete with
Bancwest, USBN, or any of their subsidiaries or affiliates, within Walla Walla
County, Washington State.

        Director also agrees that during this two year period, Director will not
directly or indirectly solicit or attempt to solicit (1) any employees of
Bancwest, USBN, or any of their subsidiaries or affiliates, to leave their
employment or (2) any customers of Bancwest, USBN, or any of their subsidiaries
or affiliates to remove their business from Bancwest, USBN, or any of their
subsidiaries or affiliates, or to participate in any manner in any financial
institution or trust company that competes or will compete with Bancwest, USBN,
or any of their subsidiaries or affiliates, within Walla Walla County,
Washington State. Solicitation prohibited under this section includes
solicitation by any means, including, without limitation, meetings, telephone
calls, letters or other mailings, electronic communication of any kind, and
internet communications.

        For purposes of this Agreement, the term "principal shareholder" means
any person who owns, directly or indirectly, five percent (5%) or more of the
outstanding shares of any class of equity security of a company.

        Director recognizes and agrees that any breach of this Agreement by
Director will entitle USBN and any of its successors or assigns to injunctive
relief and/or specific performance, as well as any other legal or equitable
remedies to which such entities may otherwise be entitled.

UNITED SECURITY BANCORPORATION         DIRECTOR


By:
   --------------------------------    -----------------------------------------
Its:
    -------------------------------
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1135 Ammonium bicarbonate. ( a ) Ammonium bicarbonate (NH4HCO3, CAS Reg. No. 1066-33-7) is prepared by reacting gaseous carbon dioxide with aqueous ammonia. Crystals of ammonium bicarbonate are precipitated from solution and subsequently washed and dried.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 19, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a dough strengthener as defined in § 170.3(o)(6) of this chapter; a leavening agent as defined in § 170.3(o)(17) of this chapter; a pH control agent as defined in § 170.3(o)(23) of this chapter; and a texturizer as defined in § 170.3(o)(32) of this chapter.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 52439, Nov. 18, 1983]
[No. 15035-6-III.

Division Three.

October 30, 1997.]

#### The State of Washington, *Respondent,*v. Julian Rangel, *Appellant.*

Appeal from a judgment of the Superior Court for Yakima County, No. 94-1-00279-7, F. James Gavin, J., entered July 7, 1995. *Affirmed*by unpublished opinion per Thompson, J., concurred in by Schultheis, A.C.J., and Kurtz, J.
Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-136211) of Wayside Technology Group, Inc. (formerly Programmer’s Paradise, Inc.) (the “Company”), pertaining to the Company’s 2006 Stock-Based Compensation Plan, and in the Registration Statement on Form S-8 (333-72249) of the Company pertaining to the Company’s  1986 Stock Option Plan, the Company’s 1995 Stock Plan and the Company’s 1995 Non-Employee Director Plan, of our report dated March 7, 2007, relating to the consolidated financial statements and financial statement schedule of the Company, which appears in the Annual Report (Form 10-K) of the Company for the year ended December 31, 2006.

| Edison, New Jersey |                                             |
|--------------------|--------------------------------------------------|
| March 9, 2007      |                                             |
|               |                                             |
|               | /s/  Amper, Politziner   & Mattia, P.C. |
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF BAB HOLDINGS, INC. FOR THE FISCAL YEARS ENDED
NOVEMBER 30, 1997 AND 1996 AND IS QUALIFIED BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
       
<S>                             <C>                     <C>
<RESTATED> 
<PERIOD-TYPE>                   12-MOS                   12-MOS
<FISCAL-YEAR-END>                          NOV-30-1997             NOV-30-1996
<PERIOD-END>                               NOV-30-1997             NOV-30-1996
<CASH>                                         389,896               2,163,293
<SECURITIES>                                         0                       0
<RECEIVABLES>                                2,576,719               1,478,098
<ALLOWANCES>                                   217,000                  30,000
<INVENTORY>                                    344,424                 103,314
<CURRENT-ASSETS>                             2,979,192               3,686,273
<PP&E>                                       5,971,601               3,833,027
<DEPRECIATION>                                 882,693                 299,315
<TOTAL-ASSETS>                              14,627,246              11,147,987
<CURRENT-LIABILITIES>                        4,295,601               2,351,220
<BONDS>                                              0                   8,133
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                  1,862,035                       0
<COMMON>                                    10,908,062               9,218,522
<OTHER-SE>                                 (4,115,347)               (423,513)
<TOTAL-LIABILITY-AND-EQUITY>                14,627,246              11,147,987
<SALES>                                      9,846,020               3,484,319
<TOTAL-REVENUES>                            14,240,956               6,640,453
<CGS>                                        3,309,504               1,221,826
<TOTAL-COSTS>                               17,572,095               6,944,217
<OTHER-EXPENSES>                               (3,701)                  12,550
<LOSS-PROVISION>                               244,232                  37,828
<INTEREST-EXPENSE>                              74,651                   4,530
<INCOME-PRETAX>                            (3,402,089)               (320,844)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                        (3,402,089)               (320,844)
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                               (4,050,286)               (320,844)
<EPS-PRIMARY>                                   (0.55)                  (0.05)
<EPS-DILUTED>                                   (0.54)                  (0.05)
        


</TABLE>
§ 556.685 Sulfaquinoxaline. ( a ) [Reserved]
( b ) *Tolerances.* The tolerances for sulfaquinoxaline are: ( 1 ) *Cattle.* Edible tissues (excluding milk): 0.1 ppm.
( 2 ) *Chickens and turkeys.* Edible tissues (excluding eggs): 0.1 ppm.
( c ) *Related conditions of use.* See §§ 520.2218, 520.2325a, 520.2325b, and 558.586 of this chapter.
[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020]